Two Schedules of Teniposide with or Without Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Topoisomerase II Inhibitors
The addition of cisplatin to VM26 improves the response rate, progression-free survival interval, and survival duration over VM26 alone, although at the cost of a significant increase in toxicity. Cisplatin should be considered as the basis for combination chemotherapies in advanced NSCLC.